INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Manufacturing Made More Robust And Customer-Centric

  Discover how regional manufacturing, risk-aware practices, and agile strategies are reshaping supply chains to deliver resilience, transparency, and sustainability in today’s complex global environment.

• Strengthen Pharmaceutical Supply Chains With A U.S.-Based CDMO

  While certain ingredients require sourcing abroad, partnering with a U.S.-based company that owns its manufacturing assets allows for direct oversight of product quality and supply reliability.

• The Team For Your Package Design Needs

  Our dedicated team of in-house design specialists deliver insightful packaging design and practical knowledge to deliver differentiated and cost-effective packaging solutions.

• Risk Mitigation For Late-Stage Clinical Assets

  Leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering.

• Cryogenic Storage Of IV Bags For Cell And Gene Therapies

  12/18/2025

  Cryogenic storage can compromise packaging integrity for cell and gene therapies. Learn how vacuum decay technology detects micro leaks and ensures product safety under extreme conditions.

• Clinical, Commercial Packaging: Delivering Next-Gen Therapies

  4/7/2026

  See how strategic, agile, and sustainable packaging is transforming drug delivery into a key driver of speed, safety, and patient-centric innovation.

• Global Complexity Demands Local Resilience

  8/31/2026

  With integrated capabilities spanning early development through commercial manufacturing, our U.S. network helps customers build greater supply chain resilience, navigate uncertainty, and create a more reliable path to market.

• From LAL To rFC: The Evolution Of Endotoxin Testing

  6/26/2026

  Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  3/16/2026

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.